Needham & Company LLC Reiterates “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Monday,Benzinga reports. They currently have a $6.00 target price on the stock. Needham & Company LLC’s price target points to a potential upside of 219.15% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group upped their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Down 8.3 %

Shares of TSHA stock opened at $1.88 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market cap of $385.29 million, a price-to-earnings ratio of 2.98 and a beta of 0.95. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32. The firm has a fifty day moving average price of $2.10 and a 200-day moving average price of $2.14.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning bought a new stake in Taysha Gene Therapies in the 3rd quarter worth approximately $28,000. Principal Financial Group Inc. bought a new stake in Taysha Gene Therapies in the second quarter worth $48,000. China Universal Asset Management Co. Ltd. raised its stake in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares in the last quarter. Intech Investment Management LLC bought a new position in Taysha Gene Therapies during the third quarter valued at $85,000. Finally, Scientech Research LLC purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter worth $97,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.